European regulators have recommended marketing authorisation for the Alzheimer's drug lecanemab (Leqembi) after an earlier negative opinion. This drug, administered biweekly, targets amyloid beta in Alzheimer's patients. While it showed promise in slowing cognitive decline, concerns about serious side effects exist. The drug is restricted to patients with specific genetic profiles and will be available through a controlled access programme. It has been approved in the US and UK, but is not available on the NHS due to cost-benefit concerns. Teljes cikk (Euronews.com)